Phaseline

Companies › Alentis Therapeutics

Alentis Therapeutics: clinical trials, targets and expected readouts

3 active drug programs in 3 registered trials: 2 Phase 1, 1 Phase 2; Oncology, Genitourinary; next expected readout Jun 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
ALE.F02
anti-CLDN1 monoclonal antibody targeting non-tight junction exposed form
CLDN1Phase 2Glomerulonephritis Rapidly ProgressiveJun 2027
ALE.P02
CLDN1-targeting therapy
–Phase 1Squamous Non-small-cell Lung CancerFeb 2028
ALE.P03
anti-CLDN1 antibody-drug conjugate
–Phase 1Cervical Squamous Cell CarcinomaApr 2029

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06047171ALE.F02Phase 2Glomerulonephritis Rapidly ProgressiveGenitourinaryJun 2027
NCT06747585ALE.P02Phase 1Squamous Non-small-cell Lung CancerOncologyFeb 2028
NCT07169734ALE.P03Phase 1Cervical Squamous Cell CarcinomaOncologyApr 2029

Targets

CLDN1 (1)

Companies with the same targets

–

Companies built like this

FutureGen Biopharmaceutical (Beijing) Hangzhou Sumgen Biotech Biokin (Shanghai) Biopharmaceutical LaNova Medicines Zhejiang I-Mab Biopharma US

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.